FDA Expands Finerenone Use for Heart Failure Patients
Finerenone Shows Critically important Benefits for Heart Failure with Preserved Ejection Fraction, Expanding Treatment Options
Table of Contents
new FDA approval offers hope for millions with a challenging form of heart failure.
The U.S. Food and Drug administration (FDA) has expanded the approved uses of finerenone (Kerendia), a medication that has now demonstrated significant benefits for patients suffering from heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). This pivotal decision, based on robust clinical trial data, offers a new therapeutic avenue for a large and growing patient population with a historically poor prognosis.
Finerenone’s Impact on Cardiovascular Outcomes
The study that underpinned this expanded approval revealed that finerenone, when added to standard medical care, resulted in a notable 16% reduction in the risk of cardiovascular death and unplanned or urgent hospitalizations due to heart failure. This benefit was primarily driven by a decrease in the worsening of heart failure events. While the drug did not show a significant effect on cardiovascular death in this specific analysis, its impact on reducing heart failure exacerbations is a critical advancement.
“A large and growing group of patients with a poor prognosis,” stated Scott Solomon, MD, a professor of medicine at Harvard Medical School and director of the Clinical Trials Outcomes center at Mass General Brigham in Boston. Dr. solomon, who chaired the executive committee for the trial, added, “Based on the clinical efficacy we saw in the FINEARTS-HF study, finerenone can become a new pillar of thorough care.”
Expanding Treatment Horizons for HFpEF
Finerenone was initially approved by the FDA in 2021. Its original indication was to reduce the risk of cardiovascular death, hospitalization for heart failure, nonfatal myocardial infarction, and kidney complications in adults with chronic kidney disease associated with type 2 diabetes. This latest decision broadens its utility,making it a valuable option for individuals with HFmrEF/HFpEF,a condition that has long presented significant treatment challenges.
Heart failure with preserved ejection fraction (HFpEF) affects approximately 3.7 million adults in the United States, according to 2024 figures from the Heart Failure Society of America. These patients often experience high rates of hospitalization,with each subsequent admission linked to a doubled risk of mortality.
“Even with current treatments, 21% of patients with symptomatic heart failure escalate to hospitalization for heart failure or [cardiovascular] death, and 25% who experience hospitalization are readmitted due to heart failure within one year of discharge,” commented Alanna Morris-Simon, MD, MSc, senior medical director of US Medical Affairs at bayer. “Now, as a core pillar of treatment, KERENDIA can definitely help patients reduce these risks.”
understanding Finerenone and Potential Side Effects
Finerenone is available in 10-,20-,and 40-mg tablet formulations. While the drug offers significant therapeutic advantages, it is indeed crucial for healthcare providers and patients to be aware of potential side effects. Patients treated with finerenone have a higher risk for hyperkalemia, a condition characterized by elevated potassium levels in the blood.
Dr. Solomon has previously noted that the risk of severe hyperkalemia can be managed. “I think we can mitigate the risk for severe hyperkalemia with these drugs,” he stated in a previous interview. Careful monitoring of potassium levels and appropriate patient selection are crucial for safe and effective use.
The drug is contraindicated for individuals with hypersensitivity to finerenone, adrenal insufficiency, or those concurrently taking strong CYP3A4 inhibitors, which can affect the drug’s metabolism.
For comprehensive prescribing information, healthcare professionals can refer to the official product labeling.